A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007.
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs.
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes.
As biotechnology patents continue to grow in importance, uncertainty remains on both sides of the Atlantic as to exactly what is patentable. Simon O’Brien and David Gass take a look.
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications.
Practitioners can take heart from recent developments in the Brazilian courts, say Otto Licks and Anderson Nascimento.
Homologation (recognition of equivalence) is a useful tool for simplifying administrative processes that are repeated in different countries. Nevertheless, it is not an end in itself.
A recent US district court ruling could significantly affect companies that patent genes and threaten the health of an entire industry. LSIPR investigates.
Two pharmaceutical cases highlight recent developments in Canadian patent law relating to duty of candour during patent prosecution and patent claim construction, says Katie Wang.